Amalgamated Bank Purchases 34,660 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Amalgamated Bank lifted its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 712.0% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 39,528 shares of the biopharmaceutical company’s stock after buying an additional 34,660 shares during the quarter. Amalgamated Bank’s holdings in TG Therapeutics were worth $925,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in TGTX. NBC Securities Inc. grew its stake in shares of TG Therapeutics by 58.9% in the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 485 shares during the last quarter. Quarry LP grew its position in shares of TG Therapeutics by 9.1% in the 2nd quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 503 shares during the last quarter. Private Advisor Group LLC increased its stake in shares of TG Therapeutics by 3.9% in the third quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company’s stock valued at $337,000 after buying an additional 542 shares during the period. Blue Trust Inc. raised its position in shares of TG Therapeutics by 127.3% during the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 849 shares during the last quarter. Finally, Swiss National Bank lifted its stake in shares of TG Therapeutics by 0.5% in the first quarter. Swiss National Bank now owns 284,100 shares of the biopharmaceutical company’s stock worth $4,321,000 after acquiring an additional 1,500 shares during the period. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Price Performance

Shares of NASDAQ:TGTX opened at $30.85 on Friday. The company’s fifty day moving average price is $24.59 and its 200-day moving average price is $20.96. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The firm has a market capitalization of $4.80 billion, a price-to-earnings ratio of -308.45 and a beta of 2.19. TG Therapeutics, Inc. has a one year low of $10.82 and a one year high of $36.50.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The firm had revenue of $83.90 million during the quarter, compared to the consensus estimate of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business’s quarterly revenue was down 49.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.73 EPS. On average, equities research analysts anticipate that TG Therapeutics, Inc. will post 0.17 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Sagar Lonial sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the sale, the director now directly owns 100,195 shares of the company’s stock, valued at approximately $3,049,935.80. This trade represents a 4.75 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 10.50% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on TGTX shares. HC Wainwright boosted their price target on shares of TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. B. Riley upped their price target on shares of TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. TD Cowen assumed coverage on TG Therapeutics in a research report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price objective for the company. Finally, The Goldman Sachs Group upped their target price on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, TG Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $37.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.